Health
Freiburg immunologists decipher anti-cancer drug’s mode of operation – News-Medical.net
Rituximab, an anti-cancer drug targeting the membrane protein CD20, was the first approved therapeutic antibody against B tumor cells. Immunologists at the University…
Rituximab, an anti-cancer drug targeting the membrane protein CD20, was the first approved therapeutic antibody against B tumor cells. Immunologists at the University of Freiburg have now solved a mystery about how it works. A team headed by Professor Dr. Michael Reth used cell cultures, healthy cells, and cells from cancer patients to investigate how CD20 organizes the nanostructures on the B cell membrane. If the protein is missing or Rituximab binds to it, the organization of the B cell surface…
-
General15 hours agoVictorian school teacher charged with soliciting child abuse material
-
Business23 hours agoWhy did this ASX 200 healthcare stock crash 14% yesterday?
-
Business22 hours agoHere’s what analysts expect for the BHP share price in the coming year
-
General23 hours agoPatients speak out after Brisbane doctor accused of ‘excessive’ pap smears, kissing woman on lips